Multi-kinase inhibitors

Current Medicinal Chemistry

Volumn 22, Issue 6, 2015, Pages 695-712

  Garuti, Laura ^a   Roberti, Marinella ^a   Bottegoni, Giovanni ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

ATP competitive; Biological activity; Heterocycles; Inhibition; Irreversible inhibitors; Kinase; Multi target; SAR

Indexed keywords

AFATINIB; BENZIMIDAZOLE DERIVATIVE; IMIDAZOPYRIDINE DERIVATIVE; IMIDAZO[1,2 B]PYRIDINE; IMIDAZO[4,5 B]PYRIDINE DERIVATIVE; INDOLIN 2 ONE; PHOSPHOTRANSFERASE INHIBITOR; PYRAZOLO[1,5 A]PYRIMIDINE DERIVATIVE; PYRAZOLO[3,4 B]PYRIDINE DERIVATIVE; PYRAZOLO[3,4 D]PYRIMIDINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE; PYRIDO[2,3 D]PYRIMIDINONE; PYRIDO[3,2 D]PYRIMIDINE; PYRIMIDINE DERIVATIVE; PYRROLO[3,2 D]PYRIMIDINE; THIAZOLO[5,4 B]PYRIDINE; UNCLASSIFIED DRUG; INDOLE DERIVATIVE; INDOLIN-2-ONE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

ARTICLE; BIOLOGICAL ACTIVITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; HUMAN; METABOLISM;

ANIMALS; HUMANS; INDOLES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRIDINES; PYRIMIDINES;

EID: 84931266088     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666141216125528     Document Type: Article

References (71)

1. Chen, Z.; Han, L.; Xu, M.; Xu, Y.; Qian, X. Rationally designed multitarget anticancer agents. Curr. Med. Chem., 2013, 20, 1694-1714.
2. Liu, X.; Zhu, F.; Ma, X. H.; Shi, Z.; Yang, S. Y,; Wei, Y. Q.; Chen, Y. Z. Predicting targeted polypharmacology for drug repositioning and multitarget drug discovery. Curr. Med. Chem., 2013, 20, 1646-1661.
3. Zhou, S.; Li, Y.; Hou, T. Feasibility of using molecular dockingbased virtual screening for searching dual target kinase inhibitors. J. Chem. Inf. Model., 2013, 53, 982-996.
4. Morphy, R. Selectively nonselective kinase inhibition: striking the right balance. J. Med. Chem., 2010, 53, 1413-1437.
5. Bologna, M.; Vicentini, C.; Muzi, P.; Pace, G.; Angelucci, A. Cancer multi target pharmacology in prostate tumors: Tyrosine kinase inhibitors and beyond. Current. Med. Chem., 2011, 18, 2827-2835.
6. O'Boyle, N. M.; Meegan, M. J. Designed multiple ligands for cancer therapy. Curr. Med. Chem., 2011, 18, 4722-4737.
7. Bolognesi, M. L. Polypharmacology in a single drug: multi target drugs. Curr. Med. Chem., 2013, 20, 1639-1645.
8. Stiepanovic, N.; Capdevila, J. Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib. Biologics, 2014, 8, 129-139.
9. Pagano, M. A.; Bain, J.; Kazimierczuk, Z.; Sarno, S.; Ruzzene, M.; Di Maira, G.; Elliott, M.; Orzeszko, A.; Cozza, G.; Meggio, F.; Pinna, L. A.; The selectivity of inhibitors of protein kinase CK2: An update. Biochem. J., 2008, 415, 353-365.
10. Roth, G. J.; Heckel, A.; Colbatzky, F.; Handschuh, S.; Kley, J.; Lehmann-Lintz, T.; Lotz, R.; Tontsch-Grunt, U.; Walter, R.; Hilbrg, F. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J. Med. Chem., 2009, 52, 4466-4480.
11. Santos, E. S.; Gomez, J. E.; Raez, L. E. Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor. Invest. New Drugs, 2012, 30, 1261-1269.
12. Cenik, B. K.; Ostapoff, K. T.; Gerber, D. E.; Brekken, R. A. BIBF 1120 (Nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. Mol. Cancer Ther., 2013, 12, 992-1001.
13. Dimitroulis, I. A. Nintedanib: A novel therapeutic approach for idiopathic pulmonary fibrosis. Respir. Care, 2014, 59
14. Howard, S.; Berdini, V.; Boulstridge, J. A.; Carr, M. G.; Cross, D. M.; Curry, J.; Devine, L. A.; Early, T. R.; Fazal, L.; Gill, A. L.; Heathcote, M.; Maman, S.; Matthews, J. E.; McMenamin, R. L.; Navarro, E. F.; O'Brien, M. A.; O'Reilly, M.; Rees, D. C.; Reule, M.; Tisi, D.; Williams, G.; Vinkovi, M.; Wyatt, P. G. Fragmentbased discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent Aurora kinase activity. J. Med. Chem., 2009, 52, 379-388.
15. Santo, L.; Hideshima, T.; Cirstea, D.; Bandi, M.; Nelson, E. A.; Gorgun, G.; Rodig, S.; Vallet, S.; Pozzi, S.; Patel, K.; Unitt, C.; Squires, M., Hu, Y.; Chauhan, D.; Mahindra, A.; Munshi, N. C.; Anderson, K. C.; Raje, N. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin. Cancer Res., 2011, 17, 3259-3271.
16. Qi, W.; Liu, X.; Cooke, L. S.; Persky, D. O.; Miller, T. P.; Squires, M.; Mahadevan, D. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. Int. J. Cancer, 2012, 130, 2997-3005.
17. Matsumoto, S.; Miyamoto, N.; Hirayama, T.; Oki, H.; Okada, K.; Tawada, M.; Iwata, H.; Nakamura, K.; Yamasaki, S.; Miki, H.; Hori, A. Structural-based design, synthesis, and evaluation of imidazo[ 1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors. Bioorg. Med. Chem., 2013, 21, 7686-7698.
18. Barf, T.; Kapten, A. Irreversible protein kinase inhibitors: balancing the benefits and risks. J. Med. Chem., 2012, 55, 6243-6262.
19. Cha, M. Y.; Lee, K-O.; Kang, S-J.; Jung, Y. H.; Song, J. Y.; Choi, K. J.; Byun, J. Y.; Lee, H-J.; Lee, G. S.; Park, S. B.; Kim, M. S. Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases. J. Med. Chem., 2012, 55, 2846-2857.
20. Ma, X. H.; Wang, R.; Tan, C. Y.; Jiang, Y. Y.; Lu, T.; Rao, H. B.; Li, X. Y.; Go, M. L.; Low, B. C.; Chen, Y. Z. Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines. Mol. Pharm., 2010, 7, 1545-1560.
21. Frey, R. R.; Curtin, M. L.; Albert, D. H.; Glaser, K. B.; Pease, L. J.; Soni, N. B.; Bouska, J. J.; Reuter, D.; Stewart, K. D.; Marcotte, P.; Bukofzer, G.; Li, J.; Davidsen, S. K.; MIchaelides, M. R. 7-Aminopyrazol[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors. J. Med. Chem., 2008, 51, 3777-3787.
22. Beffinger, M.; Skwarska, A, The role of FLT3 kinase as an AML therapy target. Curr. Pharm. Des., 2012, 8, 2758-2765.
23. Yang, L-L.; Li, G-B.; Ma, S.; Zou, C.; Zhou, S.; Sun, Q-Z.; Cheng, C.; Chen, X.; Wang, L-J.; Feng, S.; Li, L-L.; Yang, S-Y. Structureactivity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo. J. Med. Chem., 2013, 56, 1641-1655.
24. Le Brazidec, J-Y.; Pasis, A.; Tam, B.; Boykin, C.; Black, C.; Wang, D.; Claassen, G.; Chong, J-H.; Chao, J.; Fan, J.; Nguyen, K.; Silvian, L.; Ling, L.; Zhang, L.; Choi, M.; Teng, M.; Pathan, N.; Zhao, S.; Li, T. Synthesis, SAR and biological evaluation of 1,6-disubstituted-1H-pyrazolo[3,4-d]pyrimidine as dual inhibitors of Aurora kinases and CDK1. Bioorg. Med. Chem. Lett., 2012, 22, 2070-2074.
25. Ishikawa, T.; Seto, M.; Banno, H.; Kawakita, Y.; Oouri, M.; Taniguchi, T.; Ohta, Y.; Tamura, T.; Nakayama, A:, Miki, H.; Kamiguchi, H.; Tanaka, T.; Habuka, N.; Sogabe, S.; Yano, J.; Aertgeerts, K.; Kamiytama, K. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. J. Med. Chem., 2011, 54, 8030-8050.
26. Lo Russo, P.; Venkatakrishnan, K.; Chiorean, E. G.; Noe, D.; Wu, J. T.; Sankoh, S.; Corvez, M.; Sausville, E. A. Phase 1 doseescalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2. Invest. New Drugs, 2014, 32, 160-170.
27. Aertgeerts, K.; Skene, R.; Yano, J.; Sang, B-C.; Zou, H.; Snell, G.; Jennings, A.; Iwamoto, K.; Habuka, N.; Hirokawa, A.; Ishikawa, T.; Tanaka, T.; Miki, H.; Ohta, Y.; Sogabe, S. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein, J. Biol. Chem., 2011, 286, 18756-18765.
28. Kawakita, Y.; Miwa, K.; Seto, M.; Banno, H.; Ohta, Y.; Tamura, T.; Yusa, T.; Miki, H.; Kamiguchi, H.; Ikeda, Y.; Tanaka, T.; Kamiyama, K.; Ishikawa, T. Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: for potent in vivo antitumor efficacy. Bioorg. Med. Chem., 2012, 20, 6171-6180.
29. Kawakita, Y.; Banno, H.; Ohashi, T.; Tamura, T.; Yusa, T.; Nakayama, A.; Miki, H.; Iwata, H.; Kamiguchi, H.; Tanaka, T.; Habuka, N.; Sogabe, S.; Ohta, Y.; Ishikawa, T. Design and synthesis of pyrrolo[ 3,2-d]pyrimidine human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors: exploration of novel back-pocket binders. J. Med. Chem., 2012, 55, 3975-3991.
30. Porta, C.; Paglino, C.; Mosca, A. Targeting PI3K/AKT/mTOR signaling in cancer. Front. Oncol., 2014, 4, 1-11.
31. Saurat, T.; Buron, F.; Rodrigues, N.; de Tauzia, M-L.; Colliandre, L.; Bourg, S.; Bonnet, P.; Guillaumet, G.; Akssira, M.; Corlu, A.; Guillouzo, C.; Berthier, P.; Rio, P.; Jourdan, M-L.; Bénédetti, H.; Routier, S. Design, synthesis, and biological activity of pyridopyrimidine scaffolds as novel PI3K/mTOR dual inhibitors. J. Med. Chem., 2014, 57, 613-631.
32. Leonard, J. P.; LaCasce, A. S.; Smith, M. R.; Noy, A.; Chirieac, L. R.; Rodig, S. J.; Yu, J. Q.; Vallabhajosula, S.; Schoder, H.; English, P.; Neuberg, D. S.; Martin, P.; Millenson, M. M.: Ely, S. A.: Courtney, R.: Shaik, N.: Wilner, K. D.; Randolph, S.; Van den Abbeele, A.; Chen-Kiang, S. Y.; D. Yap, J. T.; Shapiro, G. I. selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood, 2012, 119, 4597-4607.
33. Flaherty, K. T.; Lorusso, P. M.; DeMichele, A.; Abramson, V. G.; Country, R.; Randolph, S. S.; Shaik, M. N.; Wilner, K. D.; O'Dwyer, P.J.; Schwartz, G. K. Phase I, dose-escalation trial of the oral cyclindependent kinase 4/6 inhibitor PD0332991, administered using a 21-day schedule in patients with advanced cancer. Clin. Cancer Res., 2012, 18, 568-576.
34. Li, C.; Qi, L.; Bellail, A. C.; Hao, C.; Liu, T. PD-0332991 induces G1 arrest of colorectal carcinoma cells through inhibition of the cyclin-dependent kinase-6 and retinoblastoma protein axis. Oncol. Lett., 2014, 7, 1673-1678.
35. Rocca, A.; Farolfi, A.; Bravaccini, S.; Schirone, A.; Amadori, D. Palbociclib (PD 0332991): Targeting the cell cycle machinery in breast cancer. Expert. Opin. Pharmacother., 2014, 15, 407-420.
36. Reddy, M. V. R.; Akula, B.; Cosenza, S. C.; Athuluridivakar, S.; Mallireddigari, M. R.; Pallela, V. R.; Billa, V. K.; Subbaiah, D. R. C. V.; Bharathi, E. V.; Vasquez-Del Carpio, R.; Padgaonkar, A.; Baker, S. J.; Reddy, E. P. Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2, 3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclindependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5). J. Med. Chem., 2014, 57, 578-599.
37. Wang, F-Z.; Peng-Jiao, Yang, N-N:; Chuang-Yuan, Zhao, Y-L.; Liu, Q-Q.; Fei, H-R.; Zhang, J-G. PF-0461502 triggers cell cycle arrest, apoptosis and inhibits the angiogenesis in hepatocellular carcinoma cells. Toxicol. Lett., 2013, 220, 150-156.
38. Britten, C. D.; Adjei, A. A.; Millham, R.; Houk, B. E.; Borzillo, G.; Pierce, K.; Wainberg, Z. A.; Lorusso, P. M. Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer. Invest. New Drugs, 2014, 32, 510-517.
39. Cheng, H.; Hoffman, J. E.; Le, P. T.; Pairish, M.; Kania, R.; Farrell, W.; Bagrodia, S.; Yuan, J.; Sun, S.; Zhang, E.; Xiang, C.; Dalvie, D. Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series. Bioorg. Med. Chem. Lett., 2013, 23, 2787-2792.
40. Tanaka, R.; Squires, M. S.; Kimura, S.; Yokota, A.; Nagao, R.; Yamauchi, T.; Taleuchi, M.; Yao, H.; Reule, M.; Smyth, T.; Lyons, J. F.; Thompson, N. T.; Ashihara, E.; Ottmann, O. G.; Maekawa, T. Activity of the multitargeted kinase inhibitor, AT9283, in imatinibresistant BCR-ABL-positive leukemic cells. Blood, 2010, 116, 2089-2095.
41. Bose, P.; Park, H.; Al-Khafaji, J.; Grant, S. Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase. Leuk. Res. Rep.; 2013, 2, 18-20.
42. Foran, J.; Ravandi, F.; Wierda,W.; Garcia-Manero, G.; Verstovsek, S.; Kadia, T.; Burger, J.; Yule, M.; Langford, G.; Lyons, J.; Ayrton, J.; Lock, V.; Borthakur, G.; Cortes, J.; Kantarjian, H. A phase I and pharmacodynamic study of AT9283, a smallmolecule inhibitor of Aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. Clin. Lymphoma Myeloma Leuk., 2014, 14, 223-230.
43. Cozza, G.; Sarno, S.; Ruzzene, M.; Girardi, C.; Orzeszko, A.; Kazimierczuk, Z.; Zagotto, G.; Bonaiuto, E.; Di Paolo, M. L.; Pinna, L. A. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases. Biochim. Biophys. Acta, 2013, 1834, 1402-1409.
44. Cozza, G.; Girardi, C.; Ranchio, A.; Lolli, G.; Sarno, S.; Orzeszko, A.; Kazimierczuk, Z.; Battistutta, R.; Ruzzene, M.; Pinna, L. A. Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential. Cell. Mol. Life Sci., 2014, DOI 10.1007/s00018-013-1552-5.
45. Dai, Y.; Hartandi, K.; Soni, N. B.; Pease, L. J.; Reuter, D. R.; Olson, A. M.; Osterling, D. J.; Doktor, S. Z.; Albert, D. H.; Bouska, J. J.; Glaser, K. B.; Marcotte, P. A.; Stewart K. D.; Davidsen, S. K.; Michaelides, M. R. Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 386-390.
46. Goldenson, B.; Crispino, J. D. The Aurora kinases in cell cycle and leukemia, Oncogene, 2014, 14, 1-9.
47. Zhang, W.; Gao, C.; Konopleva, M.; Chen, Y.; Jacamo, R. O.; Borthakur, G.; Cortes, J. E.; Ravandi, F.; Ramachandran, A.; Andreeff, M. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct Drug combination strategies. Clin. Cancer Res., 2014, 20, 2363-2370.
48. Hsu, Y. C.; Ke, Y-Y.: Shiao, H-Y.; Lee, C-C.; Lin, W-H.; Chen, CH.; Yen, K-J.; Hsu, T-A.; Chang, C.; Hsieh, H-P. Facile identification of dual FLT3-Aurora A inhibitors: A computer-guided drug design approach. ChemMedChem., 2014, 9, 953-961.
49. Bailey, E.; Li, L.; Duffield, A. S.; Ma, H. S.; Huso, D. L.; Small, D. FLT3/D835Y mutation knock-in mice display less aggressive disease compared with FLT3/internal tandem duplication (ITD) mice. Proc. Natl. Acad. Sci. USA, 2013, 110, 21113-21118.
50. Bevetsias, V.; Large, J. M.; Sun, C.; Bouloc, N.; Kosmopoulou, M.; Matteucci, M.; Wilsher, N. E.; Martins, V.; Reynisson, J.; Atrash, B.; Faisal, A:, Urban, F.; Valenti, M.; de Haven Brandon, A.; Box, G.; Raynaud, F. I.; Workman, P.; Eccles, S. A.; Bayliss, R.; Blagg, J.; Linardopoulos, S.; McDonald, E. Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. J. Med. Chem., 2010, 53, 5213-5228.
51. Oguro, Y.; Cary, D. R.; Miyamoto, N.; Tawada, M.; Iwata, H.; Miki, H.; Hori, A.; Imamura, S. Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: discovery of 1,2,4 triazolo[1,5-a]pyridine derivatives with slow dissociation kinetics. Bioorg. Med. Chem., 2013, 21, 4714-4729.
52. Bavetsias, V.; Crumpler, S.; Sun, C.; Avery, S.; Atrash, B.; Faisal, A.; Moore, A. S.; Kosmopoulou, M.; Brown, N.; Sheldrake, P. W.; Bush, K.; Henley, A.; Box, G.; Valenti, M.; de Haven Brandon, A.; Raynaud, F. I.; Workman, P.; Eccles, S. A.; Bayliss, R.; Linardopoulos, S.; Blagg, J. Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. J. Med. Chem., 2012, 55, 8721-8734.
53. Miyamoto, N.; Sakai, N.; Hirayama, T.; Miwa, K.; Oguro, Y.; Oki, H.; Okada, K.; Takagi, T.; Iwata, H.; Awazu, Y.; Yamasaki, S.; Takeuchi, T.; Miki, H.; Hori, A.; Imamura, S. Discovery of N-[5-[5-(cyclopropylcarbonyl)aminoimidazo[1,2-b]pyridazin-6-yl)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide (TAK-593),a highly potent VEGFR2 kinase inhibitor. Bioorg. Med. Chem., 2013, 21, 2333-2345.
54. Awazu, Y.; Mizutani, A.; Nagase, Y.; Tsuchiya, S.; Nakamura, K.; Kakoi, Y.; Kitahara, O.; Takeuchi, T.; Yamasaki, S.; Miyamoto, N.; Iwata, H.; Miki, H.; Imamura, S.; Hori, A. Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of vascular endothelian growth factor and platelet-derived growth factor receptor tyrosine kinase. Cancer Sci., 2013, 104, 486-494.
55. Schroeder, G. M.; An, Y.; Cai, Z-W.; Chen, X-T.; Clark, C.; Cornelius, L. A. M.; Dai, J.; Gullo-Brown, J.; Gupta, A.; Henley, B.; Hunt, J. T.; Jeyaseelan, R.; Kamath, A.; Kim, K.; Lippy, J.; Lombardo, L. J.; Manne, V.; Oppenheimer, S.; Sack, J. S.; Schmidt, R. J.; Shen, G.; Stefanski, K.; Tokarski, J. S.; Trainor, G. L.; Wautlet, B. S.; Wei, D.; Williams, D. K.; Zhang, Y.; Zhang, Y.; Fargnoli, J.; Borzilleri, R. M. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-ozo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J. Med. Chem., 2009, 52, 1251-1254.
56. Kim, K. S.; Zhang, L.; Schmidt, R.; Cai, Z-W.; Wei, D.; Williams, D. K.; Lombardo, L. J.; Trainor, G. L.; Xie, D.; Zhang, Y.; An, Y.; Sack, J. S.; Tokarski, J. S.; Darienzo, C.; Kamath, A.; Marathe, P.; Zhang, Y.; Lippy, J.; Jeyaseelan, R.; Wautlet, S. B.; Henley, B.; Gullo-Brown, J.; Manne, V.; Hunt, J. T.; Fargnoli, J.; Borzilleri, R. M. Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities. J. Med. Chem., 2008, 51, 5330-5341.
57. Baska, F.; Szabadkai, I.; Sipos, A.; Breza, N.: Szantai-Kis, C.; Kekesi, L.; Garamvolgyi, R.; Nemes, Z.; Baska, F.; Neumann, L.; Torka, R.; Ullrich, A.; Keri, G.; Orfi, L. Pharmacophore and binding analysis of known and novel B-BRAF kinase inhibitors. Curr. Med. Chem., 2014, 21, 1938-1955.
58. Okaniwa, M.; Hirose, M.; Imada, T.; Ohashi, T.; Hayashi, Y.; Miyazaki, T.; Arita, T.; Yabuki, M.; Kakoi, K.; Kato, J.; Takagi, T.; Kawamoto, T.; Yao, S.; Sumita, A.; Tsutsumi, S.; Tottori, T.; Oki, H.; Sang, B-C.; Yano, J.; Aertgeerts, K.; Yoshida, S.; Ishikawa, T. Design and synthesis of novel DFG-out RAF/vascular endothelian growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds. J. Med. Chem., 2012, 55, 3452-3478.
59. Hirose, M.; Okaniwa, M.; Miyazaki, T.; Imada, T.; Ohashi, T.; Tanaka, Y.; Arita, T.; Yabuki, M.; Kawamoto, T.; Tsutsumi, S.; Sumita, A.; Takagi, T.; Sang, B-C.; Yano, J.; Aertgeerts, K.; Yoshida, S.; Ishikawa, T. Design and synthesis of novel DFG-out RAF/vascular endothelian growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives. Bioorg. Med. Chem., 2012, 20, 5600-5615.
60. Okaniwa, M.; Imada, T.; Ohashi, T.; Miyazaki, T.; Arita, T.; Yabuki, M.; Sumita, A.; Tsutsumi, S:, Higashikawa, K.; Takagi, T.; Kawamoto, T.; Inui, Y.; Yoshida, S., Ishikawa, T. Design and synthesis of novel DGF-out RAF/vascular endothelian growth factor receptor 2 (VEGFR2) inhibitors: 2. Synthesis and characterization of a novel imide-type prodrug for improving oral absorption. Bioorg. Med. Chem., 2012, 20, 4680-4692.
61. Liu, Q.; Sabnis, Y.; Zhao, Z.; Zhang, T.; Buhriage, S. J.; Jones, L. H.; Gray, N. S. Developing irreversible inhibitors of the protein kinase cysteinome. Chem. Biol., 2013, 20, 146-159.
62. Carmi, C.; Mor, M.; Petronini, P. G.; Alfieri, R. R. Clinical perspectives for irreversibile tyrosine kinase inhibitors in cancer. Biochem. Pharmacol. 2012, 84, 1388-1399.
63. Kwak, E. The role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancer. Oncologist, 2011, 16, 1498-1507.
64. Sanderson, K. Irreversible kinase inhibitors gain traction. Nat. Rev. Drug Discov., 2013, 12, 649-651.
65. Leproult, E.; Barluenga, S.; Moras, D.; Wurtz, J-M.; Winssinger, N. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: Application to the design of selective covalent inhibitors. J. Med. Chem., 2011, 54, 1347-1355.
66. Zhou, W.; Liu, X.; Tu, Z.; Zhang, L.; Ku, X.; Bai, F.; Zhao, Z.; Xu, Y.; Ding, K.; Li, H. Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant. J. Med. Chem., 2013, 56, 7821-7837.
67. Eskens, F. A.; Mom, C. H.; Planting, A. S.; Gietema, J. A.; Amelsberg, A.; Huisman, H.; van Doorn, L.; Burger, H.; Stopfer, P.; Verweij, J.; de Vries, E. G.; A phase I dose escalation study of BIBW2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br. J. Cancer. 2008, 15, 80-85.
68. Yang, J. C.; Shih, J. Y.; Su, W. C.; Hsia, T. C.; Tsai, C. M.; Ou, S. H.; Yu, C.J.; Chang, G. C.; Ho, C. L.; Sequist, L. V.; Dudek, A. Z.; Shahidi, M.; Cong, X. J.; Lorence, R. M.; Yang, P. C.; Miller, V. A. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung2): A phase 2 trial, Lancet Oncol., 2012, 13, 539-548.
69. Bowles, D. W.; Weickhardt, A.; Jimeno, A. Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer. Drugs Today, 2013, 49, 523-535.
70. Chen, X.; Zhu, Q.; Zhu, L.; Pei, D.; Liu, Y.; Yin, Y.; Schuler, M.; Shu, Y. Clinical perspective of abatinib in non-small cell lung cancer, Lung Cancer, 2013, 81, 155-161.
71. Awada, A. H.; Dumez, H.; Hendlisz, A.; Wolter, P.; Besse-Hammer, T.; Uttenreuther-Fischer, M.; Stopfer, P.; Fleischer, F.; Piccart, M.; Schffski, P. Phase I study of pulsatile 3-day administration of afatinib (BIBW2992) in combination with docetaxel in advanced solid tumors. Invest. New Drugs, 2013, 31, 734-741.